How to Cross-Titrate to Xanomeline-Trospium in Schizophrenia
How should clinicians switch or add xanomeline-trospium when a patient with schizophrenia is already taking an antipsychotic?
Patients with schizophrenia often remain symptomatic despite adherence or need a change because of intolerable adverse effects from dopamine-blocking antipsychotics. This workflow addresses how to start XT while tapering existing therapy in a structured, class-specific way and how to handle patients maintained on long-acting injectables.
-
Choose cross-titration for persistent symptoms or side effect burden
Consider XT cross-titration when patients remain symptomatic despite adherence to antipsychotic therapy or when recovery is limited by antipsychotic adverse effects. The panel described XT as an appropriate alternative in this setting because of its distinct mechanism and because it is not associated with metabolic dysregulation, weight gain, prolactin elevation, or EPS in the way traditional antipsychotics are. Patients should be closely monitored throughout the switch.
-
Start XT at 50 mg/20 mg the same evening
Begin XT at the starting dose of 50 mg/20 mg while tapering the existing antipsychotic. The panel specifically recommended starting the XT dose the same evening the patient is seen in clinic. Counsel patients to take XT on an empty stomach and explain that early side effects tend to wane with continued use.
-
Taper the prior antipsychotic by pharmacologic class
Use a structured, clinician-guided taper rather than abrupt discontinuation. Risperidone- and paliperidone-type agents can often be tapered over several days with minimal withdrawal risk, whereas quetiapine, olanzapine, and clozapine require a slower taper over 1 to 3 weeks to avoid rebound sedation or insomnia. Dopamine D2 partial agonists such as aripiprazole, brexpiprazole, and cariprazine may generally be discontinued more quickly because of their long half-lives.
-
Use ondansetron and monitor for decompensation during overlap
Prescribe ondansetron prophylactically to mitigate nausea and vomiting early in XT treatment. Follow patients closely during the overlap period to assess tolerability and clinical stability. If decompensation occurs during cross-titration, the panel recommended reintroducing the antipsychotic.
-
Consider dose-sparing combination treatment when needed
If monotherapy transition is not sufficient, the panel noted from clinical experience that XT at 100 mg/20 mg to 125 mg/30 mg combined with a low dose of an atypical antipsychotic often provides enhanced symptom control. They further observed that XT may be antipsychotic dose-sparing, allowing reduction of ongoing antipsychotic exposure while maintaining or improving efficacy. This approach was framed as a way to reduce long-term movement and metabolic risks linked to higher dopamine-blocking doses.
-
Handle LAIs by adding XT first and reducing later if improved
For patients maintained on a long-acting injectable, initiate XT concomitantly rather than stopping the LAI outright. Once the patient reaches a maintenance dose of XT and symptoms improve, consider down-titration of the LAI dose through shared decision-making with the patient and family or care support team. The panel presented this as a tailored strategy to reduce cumulative dopamine receptor burden.
Clinical Considerations
- XT was studied as monotherapy in clinical development, and the report states that there is currently little literature on combining XT with an antipsychotic.
- The class-specific tapering schedules are based on panel consensus and pharmacologic reasoning rather than comparative switch trials.
- The suggested dose-sparing effect of XT with concomitant antipsychotics or LAIs is based on clinical experience and should be interpreted cautiously.
Bottom Line
When switching to XT, start XT immediately, taper the prior antipsychotic according to drug class rather than abruptly, and consider later dose reduction of concomitant oral or LAI antipsychotics once XT maintenance response is established.
